Glenmark, Sun to Sell Generic Version of Trileptal in US (India)
This article was originally published in PharmAsia News
Glenmark Pharmaceuticals and Sun Pharmaceutical Industries have received approval to market a generic version of Trileptal. The drug, also known as oxcarbazepine, is an epilepsy treatment manufactured by Novartis. Last year, Novartis saw about $643 million in sales from the drug, just in the U.S. Glenmark and Sun Pharma, two of India's biggest drug manufacturers, will share the exclusive marketing rights for the generic Trileptal for 180-days. However, they may have to end up sharing the rights during this time with U.S.-based generics company Roxane Laboratories. (Click here for more
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.